Adverse Event Reporting

VAERS ID 2594316
Gender Female
Age 79
StateCode OR
Pharmaceutical Company PFIZER\BIONTECH
Lot Number CT3175
Number of vaccinations 5
Vaccinated 2022-11-08
Onset
Condition
Symptoms

Current Illness

Preexisting Conditions

Other Medications

Previous Vaccinations

Allergies

Laboratory Data

Write-up

Vaccination failure; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group.
The reporter is the patient.
An 80-year-old female patient received BNT162b2, BNT162b2 omi ba.
4-5 (BNT162B2, BNT162B2 OMI BA.
4-5), on 08Nov2022 as dose 5 (booster), single (Lot number: CT3175) at the age of 79 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 08Mar2021 as dose 1, single (Lot number: EN6206), in left arm, on 29Mar2021 as dose 2, single (Lot number: EN6201), in left arm, on 17Oct2021 as dose 3 (booster), single (Lot number: FF2593), in left arm and on 29Jun2022 as dose 4 (booster), single (Lot number: FP7139), in left arm for covid-19 immunisation.
The patient's relevant medical history and concomitant medications were not reported.
The following information was reported: VACCINATION FAILURE (medically significant), outcome "unknown"; COVID-19 (medically significant), outcome "unknown", described as "Treatment of COVID-19".
Therapeutic measures were taken as a result of vaccination failure, covid-19.
Clinical Course: Patient received Paxlovid as Treatment of COVID-19 from 21Feb2023 to 27Feb2023.
Patient took no other medication in 2 weeks.
Patient had no known allergies and had other medical histories.
; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300098568 Same reporter and patient, different product and event;